Monday, August 3, 2026 - KFF Health News
• The Department of Veterans Affairs is launching a randomized clinical trial to determine if GLP-1 drugs can reduce alcohol abuse among U.S. military veterans. • The study will specifically measure whether semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, can decrease drinking and improve overall quality of life. • This initiative targets a significant public health need, as an estimated 400,000 U.S. veterans are currently diagnosed with alcohol use disorder.
kffhealthnews.org
